Brought to you by 
QLT sells Valeant its US Visudyne rights
01 Nov 2012
Executive Summary
Valeant Pharmaceuticals International Inc. has acquired QLT Inc.’s US rights to Visudyne (verteporfin), a light-activated therapy for wet age-related macular degeneration.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
QLT sells Valeant its US Visudyne rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice